Biomea Fusion, Inc. (BMEA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US09077A1060
Biomea Fusion, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -83.51 m USD |
| EBIT | -61.80 m USD |
| Net income | -61.80 m USD |
| Diluted EPS – continuing operations | -1.18 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Biomea Fusion, Inc.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
More stocks
- VirnetX Holding Corp (VHC)
- BLUE BIOFUELS, INC. (BIOF)
- TaiRx, Inc. (6580.TWO)
- Hanchem Co,. Ltd. (457370.KQ)
- Laredo Oil, Inc. (LRDC)
- ELUTIA INC. (ELUT)
- Serina Therapeutics, Inc. (SER)
- Organto Foods Incorporated (OGO.V)
- EXOZYMES INC. (EXOZ)
- Sino Green Land Corp. (SGLA)
- Fair Value REIT-AG (FVI.F)
- Model Solution Co., Ltd. (417970.KQ)
Not investment advice. All data without warranty, price as of 16.11.2026. Details in the risk notice.